医学
己酮可可碱
帕利骨化醇
蛋白尿
糖尿病
糖尿病肾病
疾病
内科学
生物信息学
内分泌学
继发性甲状旁腺功能亢进
甲状旁腺激素
生物
钙
作者
Yi‐Chih Lin,Yu-Hsing Chang,Shan-Yi Yang,Kwan Dun Wu,Tzong‐Shinn Chu
标识
DOI:10.1016/j.jfma.2018.02.007
摘要
Diabetic kidney disease (DKD) is a major cause of morbidity and mortality in patients with diabetes mellitus and the leading cause of end-stage renal disease in the world. The most characteristic marker of DKD is albuminuria, which is associated with renal disease progression and cardiovascular events. Renal hemodynamics changes, oxidative stress, inflammation, hypoxia and overactive renin-angiotensin-aldosterone system (RAAS) are involved in the pathogenesis of DKD, and renal fibrosis plays the key role. Intensified multifactorial interventions, including RAAS blockades, blood pressure and glucose control, and quitting smoking, help to prevent DKD development and progression. In recent years, novel agents are applied for preventing DKD development and progression, including new types of glucose-lowering agents, pentoxifylline, vitamin D analog paricalcitol, pyridoxamine, ruboxistaurin, soludexide, Janus kinase inhibitors and nonsteroidal minerocorticoid receptor antagonists. In this review, recent large studies about DKD are also summarized.
科研通智能强力驱动
Strongly Powered by AbleSci AI